Lixisenatide vs Tirzepatide

Lixisenatide (brand names Adlyxin or Soliqua) is a GLP-1 receptor agonist approved only for type 2 diabetes, while tirzepatide (brand names Mounjaro or Zepbound) is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes, obesity, and obstructive sleep apnea. Lixisenatide is made by Sanofi, and tirzepatide is made by Eli Lilly. Both are taken by injection, but tirzepatide is given weekly and lixisenatide is taken daily.

AI summary of the sources below.